GGHC
FLXN

Gilder Gagnon Howe & Co’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-27,832
Closed -$219K – 324
2020
Q1 		$219K Sell
27,832
-401,269
-94% -$6.04M ﹤0.01% 239
2019
Q4 		$8.88M Sell
429,101
-70,964
-14% -$1.2M 0.09% 140
2019
Q3 		$6.85M Sell
500,065
-340,585
-41% -$4.04M 0.08% 145
2019
Q2 		$10.3M Sell
840,650
-521,736
-38% -$6.02M 0.1% 126
2019
Q1 		$17M Sell
1,362,386
-1,027,574
-43% -$13.7M 0.18% 105
2018
Q4 		$27.1M Sell
2,389,960
-271,940
-10% -$4.26M 0.38% 66
2018
Q3 		$49.8M Sell
2,661,900
-788,647
-23% -$18.1M 0.51% 61
2018
Q2 		$89.2M Sell
3,450,547
-248,695
-7% -$6.45M 0.96% 31
2018
Q1 		$82.9M Sell
3,699,242
-50,330
-1% -$1.23M 1.03% 26
2017
Q4 		$93.9M Sell
3,749,572
-212,075
-5% -$5.19M 1.26% 18
2017
Q3 		$95.8M Sell
3,961,647
-305,517
-7% -$7.18M 1.35% 18
2017
Q2 		$86.3M Sell
4,267,164
-17,248
-0.4% -$359K 1.28% 18
2017
Q1 		$115M Sell
4,284,412
-94,590
-2% -$1.93M 1.94% 8
2016
Q4 		$83.3M Buy
4,379,002
+392,904
+10% +$7.51M 1.64% 9
2016
Q3 		$77.9M Sell
3,986,098
-321,772
-7% -$5.44M 1.34% 17
2016
Q2 		$64.5M Buy
4,307,870
+927,625
+27% +$11.7M 1.28% 20
2016
Q1 		$31.1M Buy
3,380,245
+1,313,244
+64% +$15.9M 0.61% 46
2015
Q4 		$39.8M Sell
2,067,001
-205,008
-9% -$3.56M 0.64% 40
2015
Q3 		$33.8M Sell
2,272,009
-25,141
-1% -$590K 0.54% 51
2015
Q2 		$50.3M Buy
2,297,150
+4,683
+0.2% +$94.4K 0.66% 44
2015
Q1 		$51.6M Buy
2,292,467
+718,619
+46% +$16.6M 0.72% 44
2014
Q4 		$31.8M Buy
+1,573,848
New +$28.5M 0.47% 55

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Gilder Gagnon Howe & Co's FLXN Position: Q2 2020 in Review

Gilder Gagnon Howe & Co sold out of Flexion Therapeutics, Inc. (FLXN) in Q2 2020, closing a stake of 27,832 shares — an estimated $219K sold.

Gilder Gagnon Howe & Co first reported a position in FLXN in Q4 2014 and held it in 22 quarters. The position peaked at $115M in Q1 2017. 125 funds tracked by Wall St. Rank hold FLXN as of Q2 2020.

  • Gilder Gagnon Howe & Co reported no remaining Flexion Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 27,832 Flexion Therapeutics, Inc. shares in Q2 2020, an estimated $219K.
  • Gilder Gagnon Howe & Co first reported a position in Flexion Therapeutics, Inc. in Q4 2014 and held it in 22 quarters.
  • Gilder Gagnon Howe & Co's Flexion Therapeutics, Inc. position peaked at $115M in Q1 2017.
  • 125 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q2 2020.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2020, filed 14 Aug 2020.